Literature DB >> 27321035

PET-Based Thoracic Radiation Oncology.

Charles B Simone1, Sina Houshmand2, Anusha Kalbasi3, Ali Salavati4, Abass Alavi2.   

Abstract

Fluorodeoxyglucose-PET is increasingly being integrated into multiple aspects of oncology. PET/computed tomography (PET/CT) has become especially important in radiation oncology. With the increasing use of advanced techniques like intensity-modulated radiation therapy and proton therapy, PET/CT scans have played critical roles in the target delineation of tumors for radiation oncologists delivering conformal treatment techniques. Use of PET/CT is well established in lung cancer and several other thoracic malignancies. This article details the current uses of PET/CT in thoracic radiation oncology with a focus on lung cancer and describes expected future roles of PET/CT for thoracic tumors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive planning; Lung cancer; PET/CT; Personalized; Proton therapy; Radiation oncology; Stereotactic body radiation therapy; Target delineation

Mesh:

Year:  2016        PMID: 27321035     DOI: 10.1016/j.cpet.2016.03.001

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  8 in total

1.  Advances in radiation therapy for thoracic malignancies.

Authors:  Charles B Simone; Shahed N Badiyan; Pranshu Mohindra
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Breaking the dose ceiling: proton therapy for locally advanced non-small cell lung cancer.

Authors:  J Isabelle Choi; Charles B Simone
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.

Authors:  Ali Salavati; Fenghai Duan; Bradley S Snyder; Bo Wei; Sina Houshmand; Benjapa Khiewvan; Adam Opanowski; Charles B Simone; Barry A Siegel; Mitchell Machtay; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-08       Impact factor: 9.236

4.  Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study.

Authors:  Melissa A Frick; Gary D Kao; Louise Aguarin; Chimbu Chinniah; Samuel Swisher-McClure; Abigail T Berman; William P Levin; Keith A Cengel; Cristina DeCesaris; Stephen M Hahn; Jay F Dorsey; Charles B Simone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-07-02       Impact factor: 7.038

5.  A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy.

Authors:  Pegah Jahangiri; Kamyar Pournazari; Drew A Torigian; Thomas J Werner; Samuel Swisher-McClure; Charles B Simone; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-18       Impact factor: 9.236

6.  Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.

Authors:  Linping Ke; Leilei Wu; Jinming Yu; Xue Meng
Journal:  Nucl Med Commun       Date:  2021-09-01       Impact factor: 1.698

Review 7.  Imaging Strategies in Proton Therapy for Thoracic Tumors: A Mini Review.

Authors:  Carlo Algranati; Lidia Strigari
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

8.  Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.

Authors:  Linping Ke; Lu Wang; Jinming Yu; Xue Meng
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.